Hepatitis C Virus
Tarvacin phase I hepatitis C virus trial initiated
Published in Hepatitis Weekly, September 5th, 2005
The phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy.
The objectives of the trial are to evaluate safety, pharmacokinetics and viral load following a single intravenous infusion. The study is being conducted at Bach and Godofsky Infectious Diseases, the largest private infectious disease practice...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-09-05)
More Articles from Hepatitis Weekly
- Complementary & Alternative Medicine
Garlic oil and DDB have a hepatoprotective effect while lowering plasma lipids - Hepatitis B Vaccine
HBV vaccine questionable in patients receiving lamividine post liver transplant - Hepatitis B Virus
Company announces end of patient dosing in HepeX-B hepatitis B phase II trial - Hepatitis C Virus
Donor age above 50 increases risk of recurrence after liver transplantation - Hepatitis C Virus
Further study of the adiponectin/insulin resistance/HCV infection triad needed - Autoimmune Disease
MICA-mimicking peptides show promise in explaining NKG2D-related autoimmunity - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
